



Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors

Saiama N. Waqar¹ · Clifford Robinson² · Anthony J. Olszanski^{2,3} · Alexander Spira⁴ · Melissa Hackmaster⁴ · Luisa Lucas⁵ · Laura Sponton⁶ · Hulin Jin⁶ · Ursula Hering⁶ · Damien Cronier⁶ · Marianna Grinberg⁶ · Annick Seithel-Keuth⁶ · Ivan Diaz-Padilla⁷ · Jordan Berlin⁸

Published online: 28 February 2022

© The Author(s) 2022

Investigational New Drugs

<https://doi.org/10.1007/s10637-022-01216-8>

The article Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors was originally published electronically on the publisher's internet portal on 12 January 2022 without open access. The author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2022 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>),

The original article can be found online at <https://doi.org/10.1007/s10637-022-01216-8>.

✉ Jordan Berlin
jordan.berlin@vumc.org

- ¹ Division of Oncology, Washington University School of Medicine and Alvin J. Siteman Cancer Center, Saint Louis, MO, USA
- ² Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO, USA
- ³ Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
- ⁴ Medical Oncology, Virginia Cancer Specialists Research Institute and US Oncology Research, Fairfax, VA, USA
- ⁵ Merck S.L.U, Mollet del Valles, Spain, an affiliate of Merck KGaA, Darmstadt, Germany
- ⁶ The Healthcare Business of Merck KGaA, Darmstadt, Germany
- ⁷ Oncology Global Clinical Development, Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany
- ⁸ Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.